IGI LABORATORIES, INC Form 8-K July 09, 2012

## **UNITED STATES**

#### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

#### FORM 8-K

#### **CURRENT REPORT**

# PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (Date of earliest event reported): July 9, 2012

## IGI LABORATORIES, INC.

(Exact name of registrant as specified in charter)

**DELAWARE**(State or Other Jurisdiction of Incorporation)

**001-08568** (Commission file number)

**01-0355758** (I.R.S. Employer Identification Number)

# 105 Lincoln Avenue

Buena, New Jersey 08310

(Address of principal executive offices)(Zip Code)

(856) 697-1441

(Registrant s telephone number, including area code)

# Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing	g is intended to simultaneously satisfy the filing obligation of	Σf
the registrant under any of the following provisions:		

[]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425
[]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12
[]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 2.02. Results of Operations and Financial Condition.

We are furnishing with this report a slide presentation (attached as Exhibit 99.1) that may be used in presentations to investors from time to time.

#### Item 7.01. Regulation FD Disclosure.

The information disclosed in Item 2.02 above is incorporated into this Item 7.01.

The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, Results of Operations and Financial Condition, Item 7.01, Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

#### Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

#### **Exhibit**

# No. <u>Description</u>

99.1 Slide Presentation dated July 2012.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

# IGI LABORATORIES, INC.

Date: July 9, 2012

By: /s/ Jenniffer Collins

Name: Jenniffer Collins

Title: Chief Financial Officer